New LaunchJul 1, 2026, 08:56 AM
Dare Bioscience Launches Flora Sync LF5, First Direct Consumer Product
AI Summary
Dare Bioscience, Inc. announced the commercial availability of Flora Sync LF5, a vaginal probiotic capsule, marking the company's first direct consumer product revenue. This launch signifies Dare Bioscience's transition to a women's health company with a revenue-generating product. The company also provided updates on its pipeline, including the upcoming dispensing of DARE to PLAY Sildenafil Cream, the initiation of a Phase 2 study for DARE-HPV, and positive interim results for its Ovaprene Phase 3 study.
Key Highlights
- Flora Sync LF5, a vaginal probiotic capsule, is now available for order.
- This marks Dare Bioscience's first direct consumer product revenue.
- Flora Sync LF5 is available exclusively through the DARE Health Hub for $49 per box.
- DARE to PLAY Sildenafil Cream dispensing is targeted to commence this summer.
- Phase 2 clinical study for DARE-HPV initiated, with topline data expected in 2027.
- Positive interim safety and efficacy results reported for Ovaprene Phase 3 study.
Price Impact
More from DARE